OncoMatch/Clinical Trials/NCT06920810
Viscum Album for TNBC on Adjuvant Pembrolizumab
Is NCT06920810 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies viscum album for breast cancer.
Treatment: viscum album — The goal of this clinical trial is to evaluate the efficacy and safety of Viscum album extract when used in combination with pembrolizumab as adjuvant chemotherapy in adult patients (aged 19 and older) who have been diagnosed with malignant neoplasm of unilateral breast and have completed surgery. The main questions it aims to answer are: Does the addition of Viscum album improve clinical outcomes when combined with pembrolizumab as adjuvant chemotherapy? Is Viscum album safe and tolerable for use in this patient population?
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Disease stage
Excluded: Stage DISTANT METASTASIS
Presence of distant metastasis [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — localized disease
Completed surgery for localized disease
Must have received: radiation therapy — localized disease
Completed radiotherapy for localized disease
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1,500/μl platelet count (plt) ≥ 100,000/μl hemoglobin (hb) ≥ 9.0 g/dl
Kidney function
acceptable levels of creatinine
Liver function
total bilirubin, ast, and alt ≤ 3 × upper limit of normal (uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify